BioAtla (BCAB) Research & Development (2020 - 2026)
BioAtla (BCAB) posted quarterly Research & Development of $4.6 million for Q1 2026, down 62.91% year-over-year from $12.4 million in Q1 2025, and down 42.69% quarter-over-quarter from $8.0 million in Q4 2025.
BioAtla (BCAB) Research & Development (2020 - 2026) Analysis & Trends
BioAtla's Research & Development history runs 7 years deep, the most recent figure standing at $4.6 million for Q1 2026.
- In Q1 2026, Research & Development fell 62.91% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $35.8 million (down 36.75% YoY), while the FY2025 annual figure was $43.6 million, down 30.94% from the prior year.
- Research & Development for Q1 2026 stood at $4.6 million, down from $8.0 million in the prior quarter.
- The five-year high for Research & Development was $31.0 million in Q2 2023, with the low at $4.6 million in Q1 2026.
- The 5-year median for Research & Development is $16.9 million (2022), against an average of $17.3 million.
- The sharpest annual moves came in 2022 and 2026: Research & Development soared 62.36% in 2022, then tumbled 62.91% in 2026.
- BioAtla's Research & Development stood at $21.9 million in 2022, then advanced by 3.66% to $22.7 million in 2023, then slumped by 48.62% to $11.6 million in 2024, then plunged by 31.37% to $8.0 million in 2025, then tumbled by 42.69% to $4.6 million in 2026.
- Business Quant data shows BCAB's Research & Development at $4.6 million in Q1 2026, $8.0 million in Q4 2025, and $9.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 3.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Mar 31, 2026 | 4.58 Mn |
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 9.54 Mn |
| Jun 30, 2025 | 13.68 Mn |
| Mar 31, 2025 | 12.36 Mn |
| Dec 31, 2024 | 11.65 Mn |
| Sep 30, 2024 | 16.40 Mn |
| Jun 30, 2024 | 16.20 Mn |
| Mar 31, 2024 | 18.85 Mn |
| Dec 31, 2023 | 22.67 Mn |
| Sep 30, 2023 | 28.40 Mn |
| Jun 30, 2023 | 30.96 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 21.87 Mn |
| Sep 30, 2022 | 19.84 Mn |
| Jun 30, 2022 | 20.71 Mn |
| Mar 31, 2022 | 16.92 Mn |
| Dec 31, 2021 | 16.45 Mn |
| Sep 30, 2021 | 16.55 Mn |